Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 3
154
Views
7
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs

, , , , , , , & show all
Pages 304-309 | Received 04 Aug 2011, Accepted 23 Aug 2011, Published online: 01 Oct 2011

References

  • Garcia E, Limon D, Perez-De La Cruz V, Giordano M, Diaz-Muñoz M, Maldonado PD, Herrera-Mundo MN, Pedraza-Chaverri J, Santamaria A. (2008). Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic Res 42:892–902.
  • Gong QH, Pan LL, Liu XH, Wang Q, Huang H, Zhu YZ. (2011). S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-?B pathway in rats. Amino Acids 40:601–610.
  • Gong QH, Wang Q, Pan LL, Liu XH, Xin H, Zhu YZ. (2011). S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-?B pathway in rats. Brain Behav Immun 25:110–119.
  • Ma K, Liu Y, Zhu Q, Liu CH, Duan JL, Tan BK, Zhu YZ. (2011). H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S? PLoS ONE 6:e20525.
  • Nagae S, Ushijima M, Hatono S, Imai J, Kasuga S, Matsuura H, Itakura Y, Higashi Y. (1994). Pharmacokinetics of the garlic compound S-allylcysteine. Planta Med 60:214–217.
  • Rose P, Whiteman M, Moore PK, Zhu YZ. (2005). Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus Allium: the chemistry of potential therapeutic agents. Nat Prod Rep 22:351–368.
  • Toutain PL, Bousquet-Mélou A. (2004). Plasma clearance. J Vet Pharmacol Ther 27:415–425.
  • US FDA. (2001). Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
  • Wang Q, Liu HR, Mu Q, Rose P, Zhu YZ. (2009). S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol 54:139–146.
  • Wang Q, Wang XL, Liu HR, Rose P, Zhu YZ. (2010). Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production. Antioxid Redox Signal 12:1155–1165.
  • Zheng Y, Liu H, Ma G, Yang P, Zhang L, Gu Y, Zhu Q, Shao T, Zhang P, Zhu Y, Cai W. (2011). Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies. J Pharm Biomed Anal 54:1187–1191.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.